Dialog Box

Durvalumab/Tremelimumab as a therapy for advanced or metastatic sarcomas

To date, limited treatment options are available for patients with metastatic sarcoma. A phase II clinical trial was conducted to evaluate the efficacy and safety of the combination of durvalumab, an anti-PD-L1 drug, and tremelimumab, an anti-CTLA-4 drug, in patients with advanced or metastatic soft-tissue and bone sarcomas. The results of this trial were recently published in the Lancet Oncology.

This study recruited 57 adult patients who have previously received at least one line of systemic therapy. Remarkably, the combination treatment of Durvalumab/Tremelimumab was associated with 12-week progression-free survival of 49%. Grade 3-4 treatment-related adverse events were observed in a number of patients, these include increased lipase (4 patients, 7%), colitis (3 patients, 5%), pneumonitis (3 patients, 5%). Serious adverse events including colitis were reported in 9 patients (16%).

Overall, this clinical trial showed that the combination of Durvalumab/Tremelimumab is an active treatment regimen in advanced or metastatic sarcoma. Further studies are needed to determine its efficacy in specific sarcoma subtypes.

Read the full text

To learn more, please read the full article here.

The Lancet

08 September 2022
Category: News